Valsartan Hydrochlorothiazide Dispersible Tablets

Not yet clear.

Valsartan Hydrochlorothiazide is a compound preparation, which consists of valsartan and hydrochlorothiazide. 80/12.5mg: Each tablet contains 80mg of valsartan and 12.5mg of hydrochlorothiazide.

This product is white tablets.

For the treatment of mild to moderate essential hypertension where blood pressure cannot be adequately controlled with a single drug. Valsartan and hydrochlorothiazide are not suitable for the initial treatment of hypertension.

Take one tablet each time, once daily.

The safety of this product has been evaluated in more than 4,300 patients. The adverse reactions that occurred were usually mild and transient. A total of 7,616 patients were included in the three controlled trials, and the adverse events that occurred in these trials are listed in the table below. Among these 7,616 patients, 4,372 received combined treatment with valsartan and hydrochlorothiazide. Adverse events with an incidence of less than 1% include: abdominal pain, epigastric pain, anxiety, arthritis, asthenia, bronchitis, acute bronchitis, chest pain, positional dizziness, dyspepsia, dyspnea, dry mouth, erectile dysfunction, gastroenteritis, hyperhidrosis, hypoesthesia, hypokalemia, hypotension, influenza, insomnia, muscle cramps, muscle tension, nausea, nasal congestion, neck pain, edema, peripheral edema, otitis media, pain in extremities, palpitations, paresthesia, pharyngitis, frequent urination, fever, rash, sinus congestion, sinusitis, lethargy, sprains and strains, tachycardia, tinnitus, urinary tract infection, vertigo, viral infection, blurred vision, abnormal vision. It is not known whether these adverse events are treatment-related. Post-marketing data indicate that the following situations have occurred very rarely: angioedema, rash, pruritus and other hypersensitivity/allergic reactions including serum sickness and vasculitis. Very rare reports of impaired renal function and myalgia have been reported, and several cases of hydrochlorothiazide-induced pulmonary edema with granulocyte infiltration and IgG deposition in the alveolar membrane have been reported. Non-cardiogenic pulmonary edema may be a rare immune-mediated idiopathic reaction to hydrochlorothiazide.

Hypersensitivity to valsartan, hydrochlorothiazide, other sulfonamides or any of the ingredients in this product. Pregnancy (see Pregnancy and Lactation). Severe liver impairment, biliary cirrhosis or cholestasis. Severe renal failure (creatinine clearance <30 ml/min) or anuria. Refractory hypokalemia, hyponatremia or hypercalcemia and symptomatic hyperuricemia.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

If used with other drugs, drug interactions may occur. Please consult your doctor or pharmacist for details.

seal.

80/12.5mg: Each tablet contains 80mg of valsartan and 12.5mg of hydrochlorothiazide

24 months

Lunan BETTER Pharmaceutical Co., Ltd.

• Founded in:

  2003-12-16

• Address:

  No. 209, Hongqi Road, Linyi City

• Tax NO.:

  91371300756399007K

• Registered Funds:

  115 million yuan

• Website:

  Log in to view

• Email:

  Log in to view